Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

NCT04212013

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • George Washington Cancer Center Washington D.C., District of Columbia, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Mayo Clinic Cancer Center Rochester, Minnesota, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
View Trial Details
Active, not recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

NCT04626791

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Mount Sinai Hospital New York, United States
  • Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina, United States
  • University of Washington Medical Center - Montlake Seattle, Washington, United States
View Trial Details
Active, not recruiting

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

NCT03179930

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Northwestern University (Data Collection Only) Evanston, Illinois, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
View Trial Details
Active, not recruiting

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Central Alabama Research Birmingham, Alabama, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of California Davis Medical Center Sacramento, California, United States
  • Florida Cancer Specialists Bonita Springs, Florida, United States
View all 143 locations
View Trial Details

Related conditions